Results 121 to 130 of about 8,315 (221)

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Operationalizing patient flow in high-complexity service lines: a health system perspective using oncology care. [PDF]

open access: yesFront Health Serv
Figlin R   +7 more
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian   +5 more
wiley   +1 more source

How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Healthy volunteers (HVs) are essential for phase I trials, yet their recruitment and screening remain resource‐intensive and ethically complex. High screening failure (SF) rates highlight the need to evaluate and understand all aspects of the enrolment processes. We analyzed SF patterns in a large German HV cohort and explored participants' motivations,
Evelyn Krohmer   +10 more
wiley   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy